Pilocytic astrocytoma in a child with spinal muscular atrophy treated with onasemnogene abeparvovec
Open Access
- 15 February 2025
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 33 (6) , 2842-2850
Abstract
No abstract availableKeywords
Funding Information
- Novartis Gene Therapies
This publication has 48 references indexed in Scilit:
- Analysis of vector genome integrations in multicentric lymphoma after AAV gene therapy in a severe hemophilia A dogMolecular Therapy - Methods & Clinical Development, 2023
- Comparing molecular and computational approaches for detecting viral integration of AAV gene therapy constructsMolecular Therapy - Methods & Clinical Development, 2023
- Lovo‐cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB‐206 studyAmerican Journal of Hematology, 2022
- Evaluating the state of the science for adeno-associated virus integration: An integrated perspectiveMolecular Therapy, 2022
- AAV integration in human hepatocytesMolecular Therapy, 2021
- Low incidence of hepatocellular carcinoma in mice and cats treated with systemic adeno-associated viral vectorsMolecular Therapy - Methods & Clinical Development, 2021
- Natural history of infantile‐onset spinal muscular atrophyAnnals of Neurology, 2017
- Manifestations of pilocytic astrocytoma: a pictorial reviewInsights into Imaging, 2014
- No Evidence for Tumorigenesis of AAV Vectors in a Large-Scale Study in MiceMolecular Therapy, 2005
- Alveolar rhabdomyosarcoma in infantile spinal muscular atrophy: coincidence or predisposition?Neuromuscular Disorders, 2005